Old Web
English
Sign In
Acemap
>
authorDetail
>
Marianne Rosamilia
Marianne Rosamilia
Novartis
Medicine
Pathology
Renal cell carcinoma
Expanded access
Everolimus
6
Papers
712
Citations
0.01
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Everolimus in patients with metastatic renal cell carcinoma (mRCC) who are intolerant of or have progressed after prior vascular endothelial growth factor receptor–tyrosine kinase inhibitor (VEGFr-TKI) therapy: An international expanded access program (EAP).
2011
Journal of Clinical Oncology
Viktor Grünwald
Istvan Bodrogi
Kurt Miller
J. H. Machiels
Se-Hoon Lee
S. Chowdhury
R. Yuan
Marianne Rosamilia
J. L. Booth
Pierre I. Karakiewicz
Show All
Source
Cite
Save
Citations (3)
7154 An International Expanded Access Program (EAP) of RAD001 (everolimus) in patients with metastatic renal cell carcinoma (mRCC) who fail, or become intolerant of a prior vascular endothelial growth factor receptor (VEGFr) therapy
2009
Ejc Supplements
Viktor Grünwald
S.Y. Rah
Kurt Miller
Pierre I. Karakiewicz
Jean-Pascal Machiels
J.J. Hajdenberg
B. I. Rini
Marianne Rosamilia
D. Resta
Se-Hoon Lee
Show All
Source
Cite
Save
Citations (2)
Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study
2004
Blood
Martin A. Champagne
Renaud Capdeville
Mark Krailo
Wenchun Qu
Bin Peng
Marianne Rosamilia
Martine Therrien
Ulrike Zoellner
Susan M. Blaney
Mark Bernstein
Show All
Source
Cite
Save
Citations (187)
Pharmacokinetics and Pharmacodynamics of Imatinib in a Phase I Trial With Chronic Myeloid Leukemia Patients
2004
Journal of Clinical Oncology
Bin Peng
Michael Hayes
Debra Resta
Amy Racine-Poon
Brian J. Druker
Moshe Talpaz
Charles L. Sawyers
Marianne Rosamilia
John M. Ford
Peter Lloyd
Renaud Capdeville
Show All
Source
Cite
Save
Citations (438)
1